Ventricular arrhythmias and prognosis of patients after explantation of an infected ICD compared to patients with newly diagnosed heart failure using the wearable cardioverter-defibrillator. (19th May 2022)
- Record Type:
- Journal Article
- Title:
- Ventricular arrhythmias and prognosis of patients after explantation of an infected ICD compared to patients with newly diagnosed heart failure using the wearable cardioverter-defibrillator. (19th May 2022)
- Main Title:
- Ventricular arrhythmias and prognosis of patients after explantation of an infected ICD compared to patients with newly diagnosed heart failure using the wearable cardioverter-defibrillator
- Authors:
- Mueller-Leisse, J
Brunn, J
Zormpas, C
Hohmann, S
Hillmann, HAK
Eiringhaus, J
Bauersachs, J
Veltmann, C
Duncker, D - Abstract:
- Abstract: Funding Acknowledgements: Type of funding sources: None. Introduction: The wearable cardioverter-defibrillator (WCD) is a tool for temporary protection from sudden cardiac death (SCD). It is used in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) as well as in patients with a preexisting ICD indication who need explantation of the device. There is no data on long-term prognosis after the WCD in this latter group of patients. Methods: All patients receiving the WCD at a Medical School between 2012 and 2017 were analyzed. Patients with newly diagnosed HFrEF from the PROLONG-II study were compared to patients receiving the WCD after an ICD explantation. Follow-up (FU) data were analyzed after 3 months and at last available FU including WCD data, clinical status, medication, echocardiography and ECG. Results: 353 patients (69% male) with newly diagnosed HFrEF from the PROLONG-II study were compared to 29 patients (86% male) having received a WCD after explantation of an ICD (45% with secondary preventive indication). Mean baseline LVEF was 25±8% and 34±13% respectively (p<0.001). Follow-up was 2.8±1.5 and 3.2±1.8 years. WCD shocks occurred in 14 (4%) of the patients with newly diagnosed HFrEF and in 3 (10%) patients after ICD explantation (2 with a secondary preventive indication). During long-term FU, patients with an explanted ICD had a poorer prognosis compared to patients with newly diagnosed HFrEF (p=0.02), and appropriate WCDAbstract: Funding Acknowledgements: Type of funding sources: None. Introduction: The wearable cardioverter-defibrillator (WCD) is a tool for temporary protection from sudden cardiac death (SCD). It is used in patients with newly diagnosed heart failure with reduced ejection fraction (HFrEF) as well as in patients with a preexisting ICD indication who need explantation of the device. There is no data on long-term prognosis after the WCD in this latter group of patients. Methods: All patients receiving the WCD at a Medical School between 2012 and 2017 were analyzed. Patients with newly diagnosed HFrEF from the PROLONG-II study were compared to patients receiving the WCD after an ICD explantation. Follow-up (FU) data were analyzed after 3 months and at last available FU including WCD data, clinical status, medication, echocardiography and ECG. Results: 353 patients (69% male) with newly diagnosed HFrEF from the PROLONG-II study were compared to 29 patients (86% male) having received a WCD after explantation of an ICD (45% with secondary preventive indication). Mean baseline LVEF was 25±8% and 34±13% respectively (p<0.001). Follow-up was 2.8±1.5 and 3.2±1.8 years. WCD shocks occurred in 14 (4%) of the patients with newly diagnosed HFrEF and in 3 (10%) patients after ICD explantation (2 with a secondary preventive indication). During long-term FU, patients with an explanted ICD had a poorer prognosis compared to patients with newly diagnosed HFrEF (p=0.02), and appropriate WCD shocks were associated with even higher mortality in patients after ICD explantation (p=0.045). Conclusion: Patients after ICD explantation have an increased risk of ventricular arrhythmias and WCD shocks, but also show an increased risk of all-cause mortality despite wearing the WCD compared to patients with newly diagnosed HFrEF. … (more)
- Is Part Of:
- Europace. Volume 24:Supplement 1(2022)
- Journal:
- Europace
- Issue:
- Volume 24:Supplement 1(2022)
- Issue Display:
- Volume 24, Issue 1 (2022)
- Year:
- 2022
- Volume:
- 24
- Issue:
- 1
- Issue Sort Value:
- 2022-0024-0001-0000
- Page Start:
- Page End:
- Publication Date:
- 2022-05-19
- Subjects:
- Arrhythmia -- Treatment -- Periodicals
Cardiac pacing -- Periodicals
Catheter ablation -- Periodicals
Heart -- Physiology -- Periodicals
Electrophysiology -- Periodicals
617.4120645 - Journal URLs:
- http://europace.oxfordjournals.org/ ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/europace/euac053.463 ↗
- Languages:
- English
- ISSNs:
- 1099-5129
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 3829.340450
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 22017.xml